![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Purpose: This study provides a comparative survival analysis between the only two drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin, and dupilumab.
Materials and methods: A multicenter, retrospective study, was performed to assess drug survival (DS) analysis by comparing cyclosporin (CsA) and dupilumab in 247 AD adult patients. DS was determined through Kaplan Meier survival analysis. For each patient, data regarding age, sex, medical history, and, at every visit, concomitant medications or procedures, adverse events (AEs), and Eczema Area and Severity Index (EASI) were registered.
Results: At week 72, 32/247 patients (13.96%) of the dupilumab group had discontinued the drug after a mean time of treatment of 35.27 ± 11.61 weeks; therefore, the DS rate at W72 was 87.04%. The most frequent (13/32; 40.63%) reason of drug discontinuation was the achievement of complete disease remission after a mean duration of treatment of 42.28 ± 2.02 weeks. In CsA-treated patients, DS rate at W72 was 21.05% (20/95 patients). Sixty-seven out of 95 (70.53%) patients had discontinued the drug, while 8/95 (8.42%) of them were lost to follow-up during the first 12 weeks of treatment. The causes of withdrawal among the patients who stopped CsA were AEs (28/67;41.79%).
Conclusions: Dupilumab has a significant longer DS when compared to CsA.
Disclosure statement
Napolitano M acted as speaker, consultant and advisory board member for Sanofi, Abbvie, Leo Pharma; Patruno C. acted as investigator, speaker, consultant, and advisory board member for AbbVie, Eli-Lilly, Novartis, Pfizer and Sanofi; Gabriella Fabbrocini has been principal investigator in clinical trials sponsored by and/or has received personal fees from AbbVie, Abiogen, Almirall, Celgene, Eli-Lilly, Leo Pharma, Novartis, Sanofi, and UCB; Maria Mariano, Antonio Cristaudo, Stefano Dastoli, Adriana Di Guida, Mario De Lucia, Gianluca Guerrasio, Steven Paul Nisticò, Maria Passante, Flavia Pigliacelli have nothing to disclose.
Data availability statement
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.